MOLECULAR PARTNERS ADS/1 - Asset Resilience Ratio
MOLECULAR PARTNERS ADS/1 (6ML0) has an Asset Resilience Ratio of 10.19% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MOLECULAR PARTNERS ADS/1 (6ML0) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2021–2025)
This chart shows how MOLECULAR PARTNERS ADS/1's Asset Resilience Ratio has changed over time. See net assets of MOLECULAR PARTNERS ADS/1 for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down MOLECULAR PARTNERS ADS/1's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of MOLECULAR PARTNERS ADS/1.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.40 Million | 10.19% |
| Total Liquid Assets | €10.40 Million | 10.19% |
Asset Resilience Insights
- Moderate Liquidity: MOLECULAR PARTNERS ADS/1 has 10.19% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
MOLECULAR PARTNERS ADS/1 Industry Peers by Asset Resilience Ratio
Compare MOLECULAR PARTNERS ADS/1's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Royalty Pharma Plc
NASDAQ:RPRX |
Biotechnology | 0.10% |
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 4.52% |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND |
Biotechnology | 35.56% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Jiangsu Aidea Pharmaceutical Co Ltd
SHG:688488 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for MOLECULAR PARTNERS ADS/1 (2021–2025)
The table below shows the annual Asset Resilience Ratio data for MOLECULAR PARTNERS ADS/1.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.19% | €10.40 Million ≈ $12.16 Million |
€102.11 Million ≈ $119.37 Million |
-43.78pp |
| 2024-12-31 | 53.97% | €85.56 Million ≈ $100.03 Million |
€158.53 Million ≈ $185.34 Million |
-6.31pp |
| 2023-12-31 | 60.29% | €119.58 Million ≈ $139.80 Million |
€198.35 Million ≈ $231.89 Million |
-1.18pp |
| 2022-12-31 | 61.47% | €161.20 Million ≈ $188.46 Million |
€262.26 Million ≈ $306.61 Million |
+26.14pp |
| 2021-12-31 | 35.33% | €61.00 Million ≈ $71.32 Million |
€172.67 Million ≈ $201.87 Million |
-- |
About MOLECULAR PARTNERS ADS/1
Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the trea… Read more